The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Open accessAbstract
BACKGROUND: The interrogation of proteomes ("proteomics") in a highly multiplexed and efficient manner remains a coveted and challenging goal in biology and medicine. METHODOLOGY/PRINCIPAL FINDINGS: We present a new aptamer-based proteomic technology for biomarker discovery capable of simultaneously measuring thousands of proteins from small sample volumes (15 µL of serum or plasma). Our current assay measures 813 proteins with low limits of detection (1 pM median), 7 logs of overall dynamic range (~100 fM-1 µM), and 5% median coefficient of variation. This technology is enabled by a new generation of aptamers that contain chemically modified nucleotides, which greatly expand the physicochemical diversity of the large randomized nucleic acid libraries from which the aptamers are selected. Proteins in complex matrices such as plasma are measured with a process that transforms a signature of protein concentrations into a corresponding signature of DNA aptamer concentrations, which is quantified on a DNA microarray. Our assay takes advantage of the dual nature of aptamers as both folded protein-binding entities with defined shapes and unique nucleotide sequences recognizable by specific hybridization probes. To demonstrate the utility of our proteomics biomarker discovery technology, we applied it to a clinical study of chronic kidney disease (CKD). We identified two well known CKD biomarkers as well as an additional 58 potential CKD biomarkers. These results demonstrate the potential utility of our technology to rapidly discover unique protein signatures characteristic of various disease states. CONCLUSIONS/SIGNIFICANCE: We describe a versatile and powerful tool that allows large-scale comparison of proteome profiles among discrete populations. This unbiased and highly multiplexed search engine will enable the discovery of novel biomarkers in a manner that is unencumbered by our incomplete knowledge of biology, thereby helping to advance the next generation of evidence-based medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Major developments in mass spectrometry-based, antibody-based and aptamer-based proteomics over the past decade have enabled the robust quantification of thousands of proteins in single samples87–90.”
From Measuring biological age using omics data (2022) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The assay uses DNA-based slow off-rate modified aptamers (SOMAmerTM reagents) to quantify the relative abundance of approximately 7000 proteins with high specificity and limits of detection largely comparable to antibody-based assays.”
From Cross-ancestry comparison of aptamer and antibody protein measures (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Proteomic technologies, including mass spectrometry–based proteomics, aptamer-based arrays (SomaLogic), and proximity extension assay technology (Olink), are now available for the large-scale quantification and validation of thousands of proteins in human biological fluids or tissues (122–127).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RNA-Mediated Metal-Metal Bond Formation in the Synthesis of Hexagonal Palladium Nanoparticles
Gugliotti, L. A., Feldheim, D. L., & Eaton, B. E. (2004) · Science · doi:10.1126/science.1095678 · Cited by 197 · cited 2×
“This innovation was used to select catalysts, including the first RNA-catalyzed carbon-carbon bond formation [16,23].”
MethodSelf-citationRetractedLevey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405 · cited 4×
“Based on the collective knowledge of the aptamer field that has developed since its inception [13,14], we hypothesized that aptamers could make exceptional reagents for high-content proteomics.”
BackgroundInfluentialSelf-citationIn vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812 · cited 4×
“Based on the collective knowledge of the aptamer field that has developed since its inception [13,14], we hypothesized that aptamers could make exceptional reagents for high-content proteomics.”
BackgroundInfluentialKeller, A., Nesvizhskii, A. I., Kolker, E., & Aebersold, R. (2002) · Analytical Chemistry · doi:10.1021/ac025747h · Cited by 4,830 · cited 2×
“0% probability as specified by the Peptide Prophet algorithm [45].”
MethodA Statistical Model for Identifying Proteins by Tandem Mass Spectrometry
Nesvizhskii, A. I., Keller, A., Kolker, E., & Aebersold, R. (2003) · Analytical Chemistry · doi:10.1021/ac0341261 · Cited by 4,809 · cited 3×
“Protein probabilities were assigned by the Protein Prophet algorithm [44].”
MethodAssessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 2×
“Eleven subjects had early-stage CKD based on estimated GFR (Table 3) (eGFR, defined as stages 1–2, median creatinine clearance 70 ml/min/m, range 62–97 ml/min/m) and 31 had late-stage CKD (stages 3–5, median creatinine clearance 25 ml/min/m, range 7–49 ml/min/m) [33].”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 2×
“Aptamers are a class of nucleic acid-based molecules discovered twenty years ago [13,14] and have since been employed in diverse applications including therapeutics [15], catalysis [16], and now proteomics.”
BackgroundHopfield, J. J. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.10.4135 · Cited by 1,594 · cited 2×
“Inspired by classic kinetic theory of specific binding in complex mixtures [25,26], we employed kinetic manipulations to help overcome the problem of non-specific SOMAmer-protein binding.”
MethodLevey, A. S., Atkins, R., Coresh, J., Cohen, E. P., Collins, A. J., Eckardt, K.-U., Nahas, M. E., Jaber, B. L., Jadoul, M., Levin, A., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002343 · Cited by 1,516 · cited 4×
“CKD biomarkers could also be useful for monitoring disease progression and guiding treatment [28–31].”
BackgroundInfluential
Cited by
Genomic atlas of the human plasma proteome
Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., Burgess, S., Jiang, T., Paige, E., Surendran, P., et al. (2018) · Nature · doi:10.1038/s41586-018-0175-2 · Cited by 2,268
Self-citationAptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Undulating changes in human plasma proteome profiles across the lifespan
Lehallier, B., Gate, D., Schaum, N., Nanasi, T., Lee, S. E., Yousef, H., Moran Losada, P., Berdnik, D., Keller, A., Verghese, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0673-2 · Cited by 981
Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J. L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.015 · Cited by 948
“The SOMAmer quantity is measured by hybridization to microarrays (for a full description, see Gold et al., 2010).”
Self-citationAnalysis of aptamer discovery and technology
Dunn, M. R., Jimenez, R. M., & Chaput, J. C. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0076 · Cited by 938
Metadata
- Authors
- Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., Flather, D., Forbes, A., Foreman, T., Fowler, C., Gawande, B., Goss, M., Gunn, M., Gupta, S., Halladay, D., Heil, J., Heilig, J., Hicke, B., Husar, G., Janjic, N., Jarvis, T., Jennings, S., Katilius, E., Keeney, T. R., Kim, N., Koch, T. H., Kraemer, S., Kroiss, L., Le, N., Levine, D., Lindsey, W., Lollo, B., Mayfield, W., Mehan, M., Mehler, R., Nelson, S. K., Nelson, M., Nieuwlandt, D., Nikrad, M., Ochsner, U., Ostroff, R. M., Otis, M., Parker, T., Pietrasiewicz, S., Resnicow, D. I., Rohloff, J., Sanders, G., Sattin, S., Schneider, D., Singer, B., Stanton, M., Sterkel, A., Stewart, A., Stratford, S., Vaught, J. D., Vrkljan, M., Walker, J. J., Watrobka, M., Waugh, S., Weiss, A., Wilcox, S. K., Wolfson, A., Wolk, S. K., Zhang, C., & Zichi, D.
- Affiliations
- University of Colorado Boulder (US)
- SomaLogic (United States) (US)
- Cornell University (US)
- Corresponding author
- Gold, Larry
- Walker, Jeffrey J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-07
- Volume
- 5
- Issue
- 12
- Pages
- e15004
- ISSN
- 1756-0357 (ISSN-L)
- 1932-6203
- PMC
- PMC3000457
- OpenAlex
- W2084373725
- Cited by
- 1,754
- References
- 46
- Citations by year
- 2026: 164 · 2025: 190 · 2024: 170 · 2023: 154 · 2022: 184 · 2021: 127 · 2020: 115 · 2019: 105 · 2018: 95 · 2017: 98 · 2016: 78 · 2015: 73 · 2014: 60 · 2013: 56 · 2012: 50
- Type
- posted content
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Nature Precedings (publishedVersion, cc-by)
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Nature Precedings (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- aptamer-based proteomics, biomarker discovery, chemically modified nucleotides, DNA microarrays, plasma protein profiling, chronic kidney disease, multiplexed protein quantification, aptamer selection, disease biomarkers
- MeSH terms
- Aged, Female, Genetic Techniques, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Kinetics, Male, Middle Aged, Nucleic Acid Hybridization, Mass Spectrometry, Reproducibility of Results, Biomarkers, Gene Library, Evidence-Based Medicine, Oligonucleotide Array Sequence Analysis, Proteome, Proteomics, Aptamers, Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. https://app.cochat.ai/papers/10.1371/journal.pone.0015004
- The paper
- Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., Flather, D., Forbes, A., Foreman, T., Fowler, C., Gawande, B., Goss, M., Gunn, M., Gupta, S., Halladay, D., . . . Zichi, D. (2010). Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. PLoS ONE. https://doi.org/10.1371/journal.pone.0015004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.